Mayne Pharma Group Reports Higher Fiscal Q3 Revenue

MT Newswires Live

Apr 29

Mayne Pharma Group (ASX:MYX) reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.

The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.

Mayne Pharma said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2631553185"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631553185\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631553185?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 08:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631553185","market":"hk","top_or_hot":-1,"title":"Mayne Pharma Group Reports Higher Fiscal Q3 Revenue","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/MAYNF\">Mayne Pharma</a> Group (ASX:MYX) reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.</p><p>The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.</p><p><a href=\"https://laohu8.com/S/MYX.AU\">Mayne Pharma</a> said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mayne Pharma Group Reports Higher Fiscal Q3 Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMayne Pharma Group Reports Higher Fiscal Q3 Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-29 08:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/MAYNF\">Mayne Pharma</a> Group (ASX:MYX) reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.</p><p>The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.</p><p><a href=\"https://laohu8.com/S/MYX.AU\">Mayne Pharma</a> said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYX.AU","symbol_name":"MAYNE PHARMA GROUP LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2631553185","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631553185","pubTimestamp":1777423296,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mayne Pharma Group  reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.Mayne Pharma said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYX.AU":"MAYNE PHARMA GROUP LTD","BK7096":"制药","BK7508":"医药生物股"},"translate_title":"梅恩制药集团报告第三财季收入增加","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYX.AU":1},"content_text":"Mayne Pharma Group (ASX:MYX) reported unaudited fiscal third-quarter revenue of AU$85.2 million, up 1% from AU$84.3 million a year earlier, according to a Wednesday filing with the Australian bourse.The company also reported underlying loss before interest, taxes, depreciation, and amortization of AU$1.4 million, an improvement from a AU$3.3 million loss in the year-ago period.Mayne Pharma said it continues to evaluate capital allocation strategies, including a potential on-market share repurchase.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}